Alnylam Pharmaceuticals (ALNY) News Today $273.55 +14.16 (+5.46%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$273.35 -0.20 (-0.07%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Up 4% on Analyst UpgradeMay 6 at 1:11 AM | americanbankingnews.comAlnylam to Webcast Presentation at BofA Securities 2025 Health Care ConferenceMay 5 at 2:50 PM | finance.yahoo.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Posts Earnings ResultsAlnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the firm posted ($0.16) EPS. The business's revenue for the quarter was up 20.2% compared to the same quarter last year.May 5 at 9:24 AM | marketbeat.comThe Manufacturers Life Insurance Company Sells 82,280 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)The Manufacturers Life Insurance Company lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 43.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,102 shMay 5 at 4:52 AM | marketbeat.comAnalyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter ReportMay 4 at 1:02 PM | finance.yahoo.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $325.00Chardan Capital upped their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday.May 4 at 8:30 AM | marketbeat.comNorthern Trust Corp Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Northern Trust Corp boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 878,860 shares of the biopharmaceuticalMay 4 at 5:05 AM | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, UBS Group Analyst SaysMay 4 at 2:34 AM | americanbankingnews.comNarrow-Moat Alnylam's Strong Patient Uptake Drives Growth; Diverse Pipeline Makes ProgressMay 3 at 4:59 PM | morningstar.comAlnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period ProgressMay 3 at 11:58 AM | seekingalpha.comAlnylam Pharmaceuticals First Quarter 2025 Earnings: Beats ExpectationsMay 3 at 11:58 AM | finance.yahoo.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at StockNews.comMay 3 at 1:49 AM | americanbankingnews.comQ1 2025 Alnylam Pharmaceuticals Inc Earnings CallMay 2, 2025 | uk.finance.yahoo.comAlnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ...May 2, 2025 | finance.yahoo.comAlnylam reiterates 2025 guidance with projected 36% growth in TTR franchise revenuesMay 2, 2025 | msn.comVoleon Capital Management LP Purchases New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Voleon Capital Management LP purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 37,181 shares of the biopharmaceutical comMay 2, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to Hold Rating by StockNews.comStockNews.com cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday.May 2, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Dimensional Fund Advisors LPDimensional Fund Advisors LP boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 333,661 shares of the biopharmaceutical company's stock after acquiring an additionalMay 2, 2025 | marketbeat.comDecoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT InsightMay 2, 2025 | gurufocus.com$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much TodayMay 1, 2025 | benzinga.comAlnylam Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 1, 2025 | seekingalpha.comSchonfeld Strategic Advisors LLC Has $29.88 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Schonfeld Strategic Advisors LLC raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 355.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 127,000 shares of the biMay 1, 2025 | marketbeat.comAQR Capital Management LLC Raises Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)AQR Capital Management LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 60.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 813,356 shares of the biopharmaceutMay 1, 2025 | marketbeat.comBridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales ExpectationsApril 30, 2025 | msn.comNovartis to acquire Regulus in deal for kidney disease drugApril 30, 2025 | finance.yahoo.comHsbc Holdings PLC Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Hsbc Holdings PLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 61,582 shares of the biopharmaceutical company's stock after acquirinApril 30, 2025 | marketbeat.comPfizer cuts spending on weaker sales after obesity failureApril 29, 2025 | detroitnews.comArtia Global Partners LP Increases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Artia Global Partners LP lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 61.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,400 shares of the biopharmaceutical company's stocApril 29, 2025 | marketbeat.com56,585 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Susquehanna Fundamental Investments LLCSusquehanna Fundamental Investments LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 56,585 shares of the biopharmaceutical company's stock, vaApril 29, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 22,944 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Adage Capital Partners GP L.L.C. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 93,056 shares of the biopharmaceutical company's stock after selling 22,944 sApril 29, 2025 | marketbeat.comMML Investors Services LLC Acquires 7,652 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)MML Investors Services LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 248.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,738 shares of the biopharmaceutical company's stock afteApril 29, 2025 | marketbeat.comAlnylam Pharmaceuticals' Vutrisiran Gets CHMP Positive OpinionApril 28, 2025 | marketwatch.comAlnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In EuropeApril 28, 2025 | finance.yahoo.comAlnylam, Halozyme among latest firms to win EU backing for drugsApril 28, 2025 | msn.comAlnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyApril 28, 2025 | businesswire.comAquatic Capital Management LLC Purchases 20,143 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Aquatic Capital Management LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 98.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,552 shares of the biopharmaceuticApril 28, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Sells 18,530 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Gilder Gagnon Howe & Co. LLC reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 365,463 shares of the biopharmaceutical company'sApril 28, 2025 | marketbeat.comCHMP gives positive opinion on marketing authorization variation for AmvuttraApril 26, 2025 | markets.businessinsider.comPrice T Rowe Associates Inc. MD Sells 132,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Price T Rowe Associates Inc. MD cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,319,385 shares of the biopharmaceutical companyApril 26, 2025 | marketbeat.comTower Research Capital LLC TRC Raises Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Tower Research Capital LLC TRC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 894.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,381 shares of the biopharmaceutical coApril 26, 2025 | marketbeat.comAlnylam Pharmaceuticals (ALNY) to Release Quarterly Earnings on ThursdayAlnylam Pharmaceuticals (NASDAQ:ALNY) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-alnylam-pharmaceuticals-inc-stock/)April 26, 2025 | marketbeat.comAlnylam stock rises following CHMP’s positive opinion on AmvuttraApril 25, 2025 | investing.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Holdings Lifted by T. Rowe Price Investment Management Inc.T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 39.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,384,449 shares of the biopharmaceutical company's stock after acquiring aApril 25, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Rating Increased to Buy at StockNews.comStockNews.com raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday.April 24, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by J. Safra Sarasin Holding AGJ. Safra Sarasin Holding AG increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 69.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,142 shares of the biopharmaceutical company's stock after buying an additional 7,868 sApril 24, 2025 | marketbeat.comFirst Trust Advisors LP Buys 42,211 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)First Trust Advisors LP lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 327,782 shares of the biopharmaceutical company's stock after buyApril 24, 2025 | marketbeat.comLobbying Update: $60,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosedApril 23, 2025 | nasdaq.comTD Cowen Keeps Their Buy Rating on Alnylam Pharma (ALNY)April 23, 2025 | markets.businessinsider.comRock Springs Capital Management LP Has $60.29 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Rock Springs Capital Management LP raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 256,200 shares of the biopharmaceutical company's stock after buying aApril 23, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by BI Asset Management Fondsmaeglerselskab A SBI Asset Management Fondsmaeglerselskab A S increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,755 shares of the biApril 23, 2025 | marketbeat.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.550.72▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼3414▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News BioMarin Pharmaceutical News Incyte News Exelixis News Neurocrine Biosciences News Exact Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALNY Stock Free ALNY Stock Alerts